Vertex Pharmaceuticals marked a -1.0% change today, compared to 1.0% for the S&P 500. Is it a good value at today's price of $351.16? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:
-
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
-
Vertex Pharmaceuticals belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 30.21 and an average price to book (P/B) of 4.08
-
The company's P/B ratio is 5.48
-
Vertex Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of 26.4 based on its trailing 12 month price to earnings (EPS) of $13.31 per share
-
Its forward P/E ratio is 21.2, based on its forward earnings per share (EPS) of $16.54
-
VRTX has a Price to Earnings Growth (PEG) ratio of 2.2, which shows the company is overvalued when we factor growth into the price to earnings calculus.
-
Over the last four years, Vertex Pharmaceuticals has averaged free cash flows of $2.7 Billion, which on average grew 23.7%
-
VRTX's gross profit margins have averaged 36.7 % over the last four years and during this time they had a growth rate of 11.4 % and a coefficient of variability of 97.7 %.
-
Vertex Pharmaceuticals has moved 9.0% over the last year compared to 14.0% for the S&P 500 -- a difference of -5.0%
-
VRTX has an average analyst rating of buy and is -12.21% away from its mean target price of $400.0 per share